Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025GlobeNewsWire • 07/23/25
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in FocusZacks Investment Research • 07/14/25
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EUZacks Investment Research • 06/25/25
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPEGlobeNewsWire • 06/24/25
Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 06/10/25
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025GlobeNewsWire • 04/28/25
Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of UnderperformanceBusiness Wire • 03/19/25
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoGlobeNewsWire • 03/19/25
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol LoweringGlobeNewsWire • 02/27/25
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025GlobeNewsWire • 02/19/25
After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)Zacks Investment Research • 11/19/24